A Study of DSP-7888 in Pediatric Patients With Relapsed or Refractory High Grade Gliomas

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

January 31, 2020

Study Completion Date

January 31, 2020

Conditions

GlioblastomaDiffuse Intrinsic Pontine Glioma

Interventions

DRUG

DSP-7888

Phase1 portion: 1.75 or 3.5 mg/body, Id every 1-4 weeks Phase 2 portion: recommended phase 2 dose, Id every 1-4 weeks

Trial Locations (6)

National Hospital Organization Nagoya Medical Center, Nagoya

Kanagawa Children's Medical Center, Yokohama

Osaka University Hospital, Suita

National Center for Child Health and Development, Setagaya City

Hiroshima University Hospital, Hiroshima

Osaka City General Hospital, Osaka

All Listed Sponsors

lead

Sumitomo Pharma Co., Ltd.

INDUSTRY

NCT02750891 - A Study of DSP-7888 in Pediatric Patients With Relapsed or Refractory High Grade Gliomas | Biotech Hunter | Biotech Hunter